[{"id":"f270357c-b837-458a-950f-910b0ee31575","acronym":"","url":"https://clinicaltrials.gov/study/NCT01587352","created_at":"2023-11-26T19:51:41.019Z","updated_at":"2024-07-02T16:35:00.381Z","phase":"Phase 2","brief_title":"Vorinostat in Treating Patients With Metastatic Melanoma of the Eye","source_id_and_acronym":"NCT01587352","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GNAQ • BAP1 • GNA11","pipe":"","alterations":" ","tags":["GNAQ • BAP1 • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/29/2012","start_date":" 05/29/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-29"},{"id":"711124ce-0659-42bd-8b65-60940e5975b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05415072","created_at":"2022-06-10T12:58:54.272Z","updated_at":"2024-07-02T16:35:07.121Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","source_id_and_acronym":"NCT05415072","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" GNAQ","pipe":"","alterations":" ","tags":["GNAQ"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DYP688"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-04-29"},{"id":"1a19387e-f25a-41bd-b670-cc6fddc92951","acronym":"Nautilus","url":"https://clinicaltrials.gov/study/NCT05340621","created_at":"2022-04-22T14:53:50.824Z","updated_at":"2024-07-02T16:35:15.772Z","phase":"Phase 1/2","brief_title":"NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)","source_id_and_acronym":"NCT05340621 - Nautilus","lead_sponsor":"OnKure, Inc.","biomarkers":" BRAF • NRAS • KIT • NF1 • GNAQ","pipe":" | ","alterations":" NRAS mutation • RAS mutation","tags":["BRAF • NRAS • KIT • NF1 • GNAQ"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • bocodepsin (OKI-179)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/11/2022","start_date":" 05/11/2022","primary_txt":" Primary completion: 03/04/2026","primary_completion_date":" 03/04/2026","study_txt":" Completion: 04/04/2026","study_completion_date":" 04/04/2026","last_update_posted":"2024-03-07"},{"id":"95f1caad-e2a9-49d6-a746-27399eb328fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439357","created_at":"2021-01-18T21:22:14.497Z","updated_at":"2024-07-02T16:35:19.658Z","phase":"Phase 2","brief_title":"Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)","source_id_and_acronym":"NCT04439357","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GNAQ • GNA11","pipe":" | ","alterations":" GNAQ mutation • GNA11 mutation","tags":["GNAQ • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GNAQ mutation • GNA11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 02/25/2016","start_date":" 02/25/2016","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-13"},{"id":"717e3712-78d8-4f21-ab42-1fd6c0efe2e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01334008","created_at":"2021-01-18T05:26:18.539Z","updated_at":"2024-07-02T16:35:21.523Z","phase":"","brief_title":"Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma","source_id_and_acronym":"NCT01334008","lead_sponsor":"Institut Curie","biomarkers":" GNAQ","pipe":"","alterations":" ","tags":["GNAQ"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2024-01-31"},{"id":"6ed5215e-5228-4ee7-8f80-16805303ee59","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922880","created_at":"2021-01-18T19:17:57.870Z","updated_at":"2024-07-02T16:35:56.988Z","phase":"Phase 1","brief_title":"Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma","source_id_and_acronym":"NCT03922880","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" GNAQ • GNA11 • CYSLTR2 • PLCB4","pipe":"","alterations":" ","tags":["GNAQ • GNA11 • CYSLTR2 • PLCB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Hepacid (pegargiminase)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 01/20/2023","primary_completion_date":" 01/20/2023","study_txt":" Completion: 01/20/2023","study_completion_date":" 01/20/2023","last_update_posted":"2023-01-26"},{"id":"f70ef90a-fdc9-405b-b396-50a810ed6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05273099","created_at":"2022-03-10T14:58:06.191Z","updated_at":"2024-07-02T16:36:13.173Z","phase":"","brief_title":"Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma","source_id_and_acronym":"NCT05273099","lead_sponsor":"Università degli Studi di Ferrara","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A","pipe":" | ","alterations":" JAK3 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-12"},{"id":"fbb7d698-9f0e-4c48-8128-78efb036d790","acronym":"","url":"https://clinicaltrials.gov/study/NCT01328106","created_at":"2021-01-18T05:24:47.264Z","updated_at":"2024-07-02T16:37:15.572Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma","source_id_and_acronym":"NCT01328106","lead_sponsor":"GlaxoSmithKline","biomarkers":" GNAQ • GNA11","pipe":" | ","alterations":" GNAQ mutation • GNA11 mutation","tags":["GNAQ • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GNAQ mutation • GNA11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 08/01/2011","primary_completion_date":" 08/01/2011","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2017-12-12"},{"id":"b28bc4bf-2724-470d-a200-8e1a03612399","acronym":"","url":"https://clinicaltrials.gov/study/NCT01143402","created_at":"2021-01-17T17:53:31.374Z","updated_at":"2024-07-02T16:37:19.584Z","phase":"Phase 2","brief_title":"Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye","source_id_and_acronym":"NCT01143402","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GNAQ • GNA11 • CYP1A2","pipe":" | ","alterations":" GNAQ mutation","tags":["GNAQ • GNA11 • CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GNAQ mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Koselugo (selumetinib) • dacarbazine"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2017-07-26"},{"id":"80df7b6e-ddde-4bae-9a86-d126eca09c34","acronym":"EMR 200066-006","url":"https://clinicaltrials.gov/study/NCT01390818","created_at":"2021-01-18T05:42:31.509Z","updated_at":"2024-07-02T16:37:24.658Z","phase":"Phase 1","brief_title":"Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT01390818 - EMR 200066-006","lead_sponsor":"EMD Serono","biomarkers":" EGFR • HER-2 • KRAS • BRAF • NRAS • PTEN • KIT • GNAQ • GNA11","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • NRAS • PTEN • KIT • GNAQ • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pimasertib (AS703026) • voxtalisib (SAR245409)"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 05/01/2011","start_date":" 05/01/2011","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2017-03-07"}]